

**TOXICOLOGICAL PROFILE FOR
MIREX AND CHLORDECONE**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry**

August 1995

DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

UPDATE STATEMENT

Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology/Toxicology Information Branch
1600 Clifton Road NE, E-29
Atlanta, Georgia 30333

FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by ATSDR and EPA. The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance being described. Each profile identifies and reviews the key literature (that has been peer-reviewed) that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

Each toxicological profile begins with a public health statement, that describes in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protect public health will be identified by ATSDR and EPA. The focus of the profiles is on health and toxicologic information; therefore, we have included this information in the beginning of the document.

Each profile must include the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance in order to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects.
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects.
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the federal, state, and local levels, interested private sector organizations and groups, and members of the public.

The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed the Agency for Toxic Substances and Disease Registry (ATSDR) to prepare toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the Environmental Protection Agency (EPA). The availability of the revised priority list of 275 hazardous substances was announced in the Federal Register on February 28, 1994 (59 FR 9486). For prior versions of the list of substances, see notices dated April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); and October 17, 1991 (56 FR 52166); and October 28, 1992 (57 FR 48801).

Foreword

Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list.

This profile reflects our assessment of all relevant toxicologic testing and information that has been peer reviewed. It has been reviewed by scientists from ATSDR, the Centers for Disease Control and Prevention (CDC), and other federal agencies. It has also been reviewed by a panel of nongovernment peer reviewers and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

A handwritten signature in black ink, appearing to read "David Satcher", with a long horizontal flourish extending to the right.

David Satcher, M.D., Ph.D.
Administrator
Agency for Toxic Substances and
Disease Registry

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHOR(S):

Obaid Faroon, Ph.D.
ATSDR, Division of Toxicology, Atlanta, GA

Steven Kueberuwa, M.S.
Research Triangle Institute, Research Triangle Park, NC

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

- 1 . Green Border Review. Green Border review assures consistency with ATSDR policy.
- 2 . Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
- 3 . Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
4. Quality Assurance Review. The Quality Assurance Branch assures that consistency across profiles is maintained, identifies any significant problems in format or content, and establishes that Guidance has been followed.

PEER REVIEW

A peer review panel was assembled for mirex and chlordecone. The panel consisted of the following members:

1. Dr. Ihn Chu, Head, Environmental Contaminants Section, Environmental Health Center, Ottawa, Ontario;
2. Dr. Syed Naqvi, Professor of Biology, Southern University, Baton Rouge, Louisiana.
3. Dr. Harihara Mehendale, Professor of Toxicology, College of Pharmacy and Health Science, Northeast Louisiana University, Monroe, Louisiana.

These experts collectively have knowledge of mirex and chlordecone's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(i)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

CONTENTS

FOREWORD	v
CONTRIBUTORS	vii
PEER REVIEW	ix
LIST OF FIGURES	xv
LIST OF TABLES	xvii
1. PUBLIC HEALTH STATEMENT	1
1.1 WHAT ARE MIREX AND CHLORDECONE?	2
1.2 WHAT HAPPENS TO MIREX AND CHLORDECONE WHEN THEY ENTER THE ENVIRONMENT?	2
1.3 HOW MIGHT I BE EXPOSED TO MIREX AND CHLORDECONE?	3
1.4 HOW CAN MIREX AND CHLORDECONE ENTER AND LEAVE MY BODY?	4
1.5 HOW CAN MIREX AND CHLORDECONE AFFECT MY HEALTH?	5
1.6 ARE THERE MEDICAL TESTS TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO MIREX OR CHLORDECONE?	7
1.7 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?	8
1.8 WHERE CAN I GET MORE INFORMATION?	8
2. HEALTH EFFECTS	11
2.1 INTRODUCTION	11
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE	11
2.2.1 Inhalation Exposure	13
2.2.1.1 Death	13
2.2.1.2 Systemic Effects	14
2.2.1.3 Immunological and Lymphoreticular Effects	16
2.2.1.4 Neurological Effects	16
2.2.1.5 Reproductive Effects	18
2.2.1.6 Developmental Effects	18
2.2.1.7 Genotoxic Effects	19
2.2.1.8 Cancer	19
2.2.2 Oral Exposure	19
2.2.2.1 Death	19
2.2.2.2 Systemic Effects	21
2.2.2.3 Immunological and Lymphoreticular Effects	84
2.2.2.4 Neurological Effects	85
2.2.2.5 Reproductive Effects	89
2.2.2.6 Developmental Effects	91
2.2.2.7 Genotoxic Effects	93
2.2.2.8 Cancer	95

2.2.3	Dermal Exposure	97
2.2.3.1	Death	98
2.2.3.2	Systemic Effects	98
2.2.3.3	Immunological and Lymphoreticular Effects	102
2.2.3.4	Neurological Effects	102
2.2.3.5	Reproductive Effects	102
2.2.3.6	Developmental Effects	103
2.2.3.7	Genotoxic Effects	103
2.2.3.8	Cancer	103
2.3	TOXICOKINETICS	104
2.3.1	Absorption	105
2.3.1.1	Inhalation Exposure	105
2.3.1.2	Oral Exposure	106
2.3.1.3	Dermal Exposure	108
2.3.2	Distribution	108
2.3.2.1	Inhalation Exposure	108
2.3.2.2	Oral Exposure	109
2.3.2.3	Dermal Exposure	114
2.3.2.4	Other Routes of Exposure	115
2.3.3	Metabolism	115
2.3.4	Excretion	118
2.3.4.1	Inhalation Exposure	118
2.3.4.2	Oral Exposure	118
2.3.4.3	Dermal Exposure	121
2.3.4.4	Other Routes of Exposure	122
2.3.5	Mechanisms of Action	123
2.4	RELEVANCE TO PUBLIC HEALTH	126
2.5	BIOMARKERS OF EXPOSURE AND EFFECT	151
2.5.1	Biomarkers Used to Identify or Quantify Exposure to Mirex or Chlordecone	152
2.5.2	Biomarkers Used to Characterize Effects Caused by Mirex or Chlordecone	153
2.6	INTERACTIONS WITH OTHER SUBSTANCES	155
2.7	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	158
2.8	METHODS FOR REDUCING TOXIC EFFECTS	159
2.8.1	Reducing Peak Absorption Following Exposure	160
2.8.2	Reducing Body Burden	160
2.8.3	Interfering with the Mechanism of Action for Toxic Effects	162
2.9	ADEQUACY OF THE DATABASE	163
2.9.1	Existing Information on Health Effects of Mirex and Chlordecone	163
2.9.2	Identification of Data Needs	166
2.9.3	Ongoing Studies	183
3.	CHEMICAL AND PHYSICAL INFORMATION	185
3.1	CHEMICAL IDENTITY	185
3.2	PHYSICAL AND CHEMICAL PROPERTIES	185

4. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	189
4.1 PRODUCTION	189
4.2 IMPORT/EXPORT	191
4.3 USE	191
4.4 DISPOSAL	192
5. POTENTIAL FOR HUMAN EXPOSURE	195
5.1 OVERVIEW	195
5.2 RELEASES TO THE ENVIRONMENT	199
5.2.1 Air	201
5.2.2 Water	202
5.2.3 Soil	204
5.3 ENVIRONMENTAL FATE	205
5.3.1 Transport and Partitioning	205
5.3.2 Transformation and Degradation	211
5.3.2.1 Air	211
5.3.2.2 Water	211
5.3.2.3 Sediment and Soil	212
5.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	215
5.4.1 Air	215
5.4.2 Water	216
5.4.3 Sediment and Soil	217
5.4.4 Other Environmental Media	220
5.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	225
5.6 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	228
5.7 ADEQUACY OF THE DATABASE	231
5.7.1 Identification of Data Needs	232
5.7.2 Ongoing Studies	235
6. ANALYTICAL METHODS	237
6.1 BIOLOGICAL SAMPLES	237
6.2 ENVIRONMENTAL SAMPLES	244
6.3 ADEQUACY OF THE DATABASE	253
6.3.1 Identification of Data Needs	254
6.3.2 Ongoing Studies	255
7. REGULATIONS AND ADVISORIES	257
8. REFERENCES	265
9. GLOSSARY	331
APPENDICES	
A. USER'S GUIDE	A-1
B. ACRONYMS, ABBREVIATIONS, AND SYMBOLS	B-1

LIST OF FIGURES

2-1	Levels of Significant Exposure to Mirex - Oral	41
2-2	Levels of Significant Exposure to Chlordecone - Oral	64
2-3	Proposed Metabolic Pathways for Chlordecone	117
2-4	Existing Information on Health Effects of Mirex	164
2-5	Existing Information on Health Effects of Chlordecone	165
5-1	Frequency of NPL Sites with Mirex Contamination	198
5-2	Frequency of NPL Sites with Chlordecone Contamination	200

LIST OF TABLES

2-1	Levels of Significant Exposure to Mirex - Oral	22
2-2	Levels of Significant Exposure to Chlordecone - Oral	44
2-3	Levels of Significant Exposure to Mirex - Dermal	99
2-4	Levels of Significant Exposure to Chlordecone - Dermal	100
2-5	Genotoxicity of Mirex and Chlordecone <i>In Vivo</i>	144
2-6	Genotoxicity of Mirex and Chlordecone <i>In Vitro</i>	145
3-1	Chemical Identity of Mirex and Chlordecone	186
3-2	Physical and Chemical Properties of Mirex and Chlordecone	187
6-1	Analytical Methods for Determining Mirex in Biological Samples	238
6-2	Analytical Methods for Determining Chlordecone in Biological Samples	241
6-3	Analytical Methods for Determining Mirex in Environmental Samples	245
6-4	Analytical Methods for Determining Chlordecone in Environmental Samples	249
7-1	Regulations and Guidelines Applicable to Mirex	259
7-2	Regulations and Guidelines Applicable to Chlordecone	262

